4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Fennec Pharmaceuticals Inc. (FRX) operates in the Biotechnology industry and is headquartered in Research Triangle Park, United States with about 35 employees. Its market capitalization is roughly C$505 million. In the fiscal year ended 2025-12-31, FRX reported $45M in revenue and ($10M) in net income.
Fennec Pharmaceuticals Inc. operates as a commercial stage biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of cisplatin-induced ototoxicity pediatric patients.
Interactive charts & full statements → Open the FRX valuation workbench →
| Income statement | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Revenue | $45M | $48M | $21M | $2M | — |
| Gross Profit | $41M | $44M | $20M | $1M | — |
| Operating Income (EBIT) | ($6M) | $2M | ($13M) | ($23M) | — |
| Net Income | ($10M) | ($0M) | ($16M) | ($24M) | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 |
|---|---|---|---|---|---|---|
| Total Revenue | $18M | $15M | $14M | $12M | $10M | — |
| Gross Profit | $17M | $14M | $12M | $12M | $9M | — |
| Operating Income (EBIT) | $2M | ($0M) | ($3M) | ($0M) | ($3M) | — |
| Net Income | $2M | $0M | ($5M) | ($1M) | ($3M) | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Assets | $71M | $45M | $27M | $27M | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive FRX viewer.
About TickerBase · Data methodology & sources · Privacy · Terms